Evidence map›Paper›PMID 26526158›Full record

ArticleJournal of neurochemistry2016

Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice.

Eva Dolejší, Ori Liraz, Vladimír Rudajev, Pavel Zimčík, Vladimír Doležal, Daniel M Michaelson

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Thicker macula in asymptomaticAlzheimer's & dementia (Amsterdam, Netherlands) · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. APOE in the normal brain.Neurobiology of disease · 2020
    Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Eva DolejšíDepartment of Neurochemistry, Institute of Physiology CAS, Vídeňská, Czech Republic.
Ori LirazDepartment of Neurobiology, Sagol School of Neurosciences, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Vladimír RudajevDepartment of Neurochemistry, Institute of Physiology CAS, Vídeňská, Czech Republic.
Pavel ZimčíkDepartment of Neurochemistry, Institute of Physiology CAS, Vídeňská, Czech Republic.
Vladimír DoležalDepartment of Neurochemistry, Institute of Physiology CAS, Vídeňská, Czech Republic.
Daniel M MichaelsonDepartment of Neurobiology, Sagol School of Neurosciences, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Czech Academy of Sciences, Institute of Physiology · CZTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein E4 (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease. We utilized apoE4-targeted replacement mice (approved by the Tel Aviv University Animal Care Committee) to investigate whether cholinergic dysfunction, which increases during aging and is a hallmark of Alzheimer's disease, is accentuated by apoE4. This revealed that levels of the pre-synaptic cholinergic marker, vesicular acetylcholine transporter in the hippocampus and the corresponding electrically evoked release of acetylcholine, are similar in 4-month-old apoE4 and apolipoprotein E3 (apoE3) mice. Both parameters decrease with age. This decrease is, however, significantly more pronounced in the apoE4 mice. The levels of cholinacetyltransferase (ChAT), acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) were similar in the hippocampus of young apoE4 and apoE3 mice and decreased during aging. For ChAT, this decrease was similar in the apoE4 and apoE3 mice, whereas it was more pronounced in the apoE4 mice, regarding their corresponding AChE and BuChE levels. The level of muscarinic receptors was higher in the apoE4 than in the apoE3 mice at 4 months and increased to similar levels with age. However, the relative representation of the M1 receptor subtype decreased during aging in apoE4 mice. These results demonstrate impairment of the evoked release of acetylcholine in hippocampus by apoE4 in 12-month-old mice but not in 4-month-old mice. The levels of ChAT and the extent of the M2 receptor-mediated autoregulation of ACh release were similar in the adult mice, suggesting that the apoE4-related inhibition of hippocampal ACh release in these mice is not driven by these parameters. Evoked ACh release from hippocampal and cortical slices is similar in 4-month-old apoE4 and apoE3 mice but is specifically and significantly reduced in hippocampus, but not cortex, of 12-month-old apoE4 mice. This effect is accompanied by decreased VAChT levels. These findings show that the hipocampal cholinergic nerve terminals are specifically affected by apoE4 and that this effect is age dependent.

Indexed as

AcetylcholineAge FactorsAnimalsApolipoprotein E3Apolipoprotein E4Choline O-AcetyltransferaseGuanosine 5'-O-(3-Thiotriphosphate)HippocampusMaleMiceMice, Inbred C57BLMice, TransgenicN-MethylscopolamineReceptors, MuscarinicTritiumVesicular Acetylcholine Transport ProteinsAcetylcholineApolipoprotein E3Apolipoprotein E4Choline O-AcetyltransferaseGuanosine 5'-O-(3-Thiotriphosphate)N-MethylscopolamineReceptors, MuscarinicSlc18a3 protein, mouseTritiumVesicular Acetylcholine Transport Proteinsacetylcholine releaseAlzheimer's disease (AD)apolipoprotein E4 (apoE4)hippocampus

Identifiers

PMID26526158
PMCPMC4738402
OpenAlexW1921550558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.